What is Thymosin beta-4?
Thymosin beta-4 is a full-length 43-residue peptide studied in tissue biology. The selected human study tested an ophthalmic preparation for dry eye, with negative primary endpoints.
Biological role or research focus
Tissue biology and ophthalmic research.
Secondary findings should be interpreted alongside failure of the primary endpoints. The ophthalmic route and dry-eye population do not establish safety or efficacy of systemic use.
Names you may encounter
Tβ4 · RGN-259
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Full-length 43-residue actin-binding peptide
- Research focus
- Tissue biology and ophthalmic research
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Quick answers
- Is Thymosin beta-4 FDA approved?
- No. No FDA-approved drug contains Thymosin beta-4. Source ↗
- Is Thymosin beta-4 safe?
- Investigational protein, not FDA-approved. Small trials of eye drops and infusions reported mostly mild side effects, but long-term and whole-body safety remain unknown. Human safety data: trials only. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Thymosin beta-4 banned in sport?
- Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.3 Growth factors and growth factor modulators). Source ↗
- Has the FDA taken action over Thymosin beta-4?
- Yes. Our records list 2 FDA actions naming it, most recently on January 20, 2026: FDA warning letter to an outsourcing facility (GenoGenix) naming Thymosin Beta-4 as an unapproved new drug and an unlicensed biological product. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| RGN-259 dry-eye phase 2 study (2015) | Human randomized trial | 72 people with moderate to severe dry eye. |
| RGN-259 · small severe dry-eye trial | Human phase 2 randomized trial | Nine patients with severe dry eye; the abstract reports outcomes for 12 treated eyes and six control eyes. |
Claim check
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2015
RGN-259 dry-eye phase 2 study
Did ophthalmic treatment meet the primary dry-eye endpoints?
- Population / model
- 72 people with moderate to severe dry eye.
- Study design
- Randomized double-masked placebo-controlled phase 2 ophthalmic study over 28 days.
- Main finding
- Neither primary endpoint—ocular discomfort nor inferior corneal staining at day 29—showed a statistically significant treatment benefit. Some secondary outcomes favored treatment.
- Limits & context
- Secondary findings should be interpreted alongside failure of the primary endpoints. The ophthalmic route and dry-eye population do not establish safety or efficacy of systemic use.
Human phase 2 randomized trial · undefined
RGN-259 · small severe dry-eye trial
What did a small ophthalmic experiment report?
- Population / model
- Nine patients with severe dry eye; the abstract reports outcomes for 12 treated eyes and six control eyes.
- Study design
- Two-site double-masked vehicle-controlled trial: 28 days of eye drops and another 28 days of follow-up.
- Main finding
- At day 56, the reported reductions relative to vehicle were 35.1% for ocular discomfort and 59.1% for total corneal fluorescein staining. Treatment was described as well tolerated.
- How to read it
- Eyes and patients are different units; 18 eyes do not mean 18 independent participants.
- Limits & context
- Very small sample and multiple assessment times limit confidence. Read beside the larger 72-person trial, which missed its primary endpoints. Ophthalmic findings do not establish systemic injury recovery or equivalence to TB-500 fragments.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
18 registered studies name Thymosin beta-4 as an intervention; 0 are recruiting or under way, 1 has not started recruiting yet, 12 completed and 5 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 18 listed studies.
Search additional PubMed records ↗Risks & interactions
Investigational protein, not FDA-approved. Small trials of eye drops and infusions reported mostly mild side effects, but long-term and whole-body safety remain unknown.
Phase 1 infusion studies in healthy volunteers reported no serious adverse events, and eye-drop trials reported few or none. These were small and short, and no long-term whole-body safety data were found.
Warning signs in animal or lab studies: Cancer, now or in the past
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. These tags come only from the studies and warnings summarized below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Harms seen in animal or lab studies
- In tumor and lab studies, higher thymosin beta-4 levels have been linked to tumor spread and blood-vessel growth
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Intravenous thymosin beta4 in healthy volunteers: phase 1 (2010) ↗ · First-in-human phase 1 study of recombinant thymosin beta4 (2021) ↗ · Thymosin beta 4 ophthalmic solution for dry eye: phase 2 (2015) ↗ · RGN-259 in neurotrophic keratopathy: phase 3 (2022) ↗ · Thymosin beta4: a potential molecular target for tumor therapy (review) ↗
What the featured evidence can tell us
No adverse events were reported in this small short study, which cannot exclude uncommon harms or establish safety across other routes.
Identity, route, and evidence limits
Secondary findings should be interpreted alongside failure of the primary endpoints. The ophthalmic route and dry-eye population do not establish safety or efficacy of systemic use.
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Full-length thymosin beta-4 was not found on FDA's 503A category lists. Its fragment TB-500 was in category 2 until the nomination was withdrawn (April 2026). source - World Anti-Doping Agency (2026)
- Prohibited, named on the list · S2.3 Growth factors and growth factor modulators
Named explicitly ("Thymosin-beta4 and its derivatives"). source
FDA actions
- FDA warning letter to an outsourcing facility (GenoGenix) naming Thymosin Beta-4 as an unapproved new drug and an unlicensed biological product. (2026-01-20) source
- FDA warning letter (Warrior Labz) citing TB-500 products described as thymosin beta-4 sold online as unapproved new drugs. (2023-06-12) source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Clinical context & research status
The featured study concerns eye drops for moderate to severe dry eye. It does not establish a systemic injury-recovery use or validate material sold as TB-500.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
How Thymosin beta-4 works
Thymosin beta-4 is associated with actin binding and tissue responses. This biological role motivates research but does not establish a clinical tissue-repair treatment.
Molecular structure
Questions worth asking
- Is thymosin beta-4 the same as TB-500?
- What population, comparator, and route were actually studied?
- Secondary findings should be interpreted alongside failure of the primary endpoints. The ophthalmic route and dry-eye population do not establish safety or efficacy of systemic use.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is thymosin beta-4 the same as TB-500?
This site distinguishes full-length thymosin beta-4 from the acetylated seven-residue TB-500 fragment shown in its separate profile. Vendor naming alone cannot establish identity.
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
PUT THE EVIDENCE IN CONTEXT
Research guides
RESEARCH FIELD GUIDE
TB-500 vs thymosin beta-4: a fragment is not the whole protein
TB-500 and thymosin beta-4 are often used as if they were the same thing. They are not, and most of the human research involves the full protein, not the fragment sold as TB-500.
Read the guide →RESEARCH FIELD GUIDE
Tissue repair peptides: which have actually been tested in people?
A roundup of popular tissue repair peptides and what has been tested in people: BPC-157's tiny human record, thymosin beta-4 eye and ulcer trials, GHK-Cu skin studies, TP-508 and LL-37 wound trials, plus FDA and WADA status.
Read the guide →RESEARCH FIELD GUIDE
Where research peptides come from, and why the batch matters more than the brand
Dozens of online shops sell research peptides, and many look like different companies selling the same products. We compared 15 shops' menus, prices and 98 of their lab reports. The pattern fits a market where many brands buy finished vials from a few manufacturers and sell them under their own labels. So the question to ask isn't "which brand?" but "was the lot I'm buying tested, and does the lab confirm it?"
Read the guide →


